We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/11/2016 22:54 | Great stuff guys and gals ... CONGRATULATIONS SUMMIT ... and typically modest, they haven't even announced it on their Twitter feed (or perhaps too busy celebrating?!) Wonderful ... hope all are enjoying a moment of glory. | hugus maximus | |
30/11/2016 22:38 | Excellent news, well done Summit !! | jag63 | |
30/11/2016 22:14 | They won !!!!! Scrip @PharmaScrip 51s52 seconds ago .@Summitplc’s Phase II CoDIFy study win #ScripAwards 2016 QuintilesIMS' Clinical Advance of the Year Award 0 replies 0 retweets 0 likes Reply Retweet Like More | chrisatrdg | |
30/11/2016 21:14 | Summit Therapeutics @Summitplc 6m6 minutes ago We've updated … w/ additional locations & contact info for PhaseOut DMD #utrophin #Duchenne | someuwin | |
30/11/2016 20:21 | Summit Therapeutics @Summitplc 32m32 minutes ago Our team is @PharmaScrip 's #ScripAwards tonight. We're shortlisted for clinical advance of the year for the Ph 2 of ridinilazole in #cdiff | someuwin | |
29/11/2016 18:37 | A number of measures in here that should be good for SUMM, including continuing with the voucher programme (ie the one we got), biomarkers and generally speeding up FDA, including specific mention of anti-biotics Edit: the voucher only gets awarded if we get approvals, but has a value in itself with a number having sold for $350m a pop | waterloo01 | |
29/11/2016 07:37 | freemoney, whoever edited the page has taken the Wainwright note as it's base. Actually it's a straight lift. | waterloo01 | |
29/11/2016 07:30 | I've noticed the Ridinilazole Wikipedia page recently. The commercialisation section seems to imply the deal has already been done. But obviously we would have been told officially if it had. Remember anyone can edit these pages. Either way it makes interesting reading for now and I'll be interested to see how far the official deal and numbers will differ.... hopefully we'll know shortly... GLA Commercialization "Ridinilazole is manufactured by Summit Therapeutics. Summit Therapeutics plans to partner with another pharmaceutical company to begin Phase 3 trials. They predict for both the US and EU launch to occur in 2021 with peak sales of £930 million. Summit will receive a flat 20% royalty rate. Models predict that royalties will rise from £25.6 million in FY2022 to £75.2 in FY2027. Ridinilazole has been de-risked with positive Phase 2 data.[4] Summit estimates that the price will be $1,200 for one course of therapy in the US and approximately 20% less in the EU. This is in contrast to Merck's Dificid (fidaxomicin) which was priced at $2,800 per course of therapy. Dificid did not sell well because it cost nearly four times as much as the generic vancomycin alternatives.[4] According to H.C. Wainwright, ridinilazole is currently undervalued since ridinilazole allows the patients gut microflora to be preserved which helps prevents deadly recurrent infections and allows for the use of ridinilazole as a first line therapy, in contrast with antibiotics already on the market. | freemoney1 | |
28/11/2016 20:08 | Not seen any notice of a webcast? Is this similar/same as Trumps idea? Could prove rather useful! | waterloo01 | |
28/11/2016 18:20 | NASDAQ still maintaining momentum - fingers crossed.Looking forward to Tuesday's webcast by Summit (hopefully if same as last year) at: OPPENHEIMER & COMPANY LIFE SCIENCES SUMMIT 29 November 2016, New York City, US Edit: Notice of webcast not yet notified but expecting RNS Tuesday (i.e. expecting per last year). | chrisatrdg | |
28/11/2016 17:55 | It's surely time for an update on RDZ. Will it mirror the SRPT deal? And who knows about the shelf zombies? I noted recently the BMS were more active (not directly relevant) | waterloo01 | |
28/11/2016 17:17 | liking the action on nasdaq..... | luminoso | |
27/11/2016 19:00 | Amyloid hypothesis loosing traction in Alzheimer's. Focus back on Tau Interesting .... Summit | freedosh | |
25/11/2016 07:48 | Morning Sorrento ... it's "the day after thanksgiving" and a Public Holiday in the USA, so highly unlikely. But there must be news soon. Meanwhile a huge opportunity to buy shares at a ridiculous Black Friday discount! | hugus maximus | |
25/11/2016 00:50 | Is today the day for C diff? | sorrento06 | |
24/11/2016 18:04 | Chris, they could have been buys at yesterdays trading range.... and I suspect they were since the price moved up. Buy 'em cheap while you still can :-) | freemoney1 | |
24/11/2016 17:57 | Large Sells gone through today dated yesterday 61k & 62k number of shares sold at £1.67 & £1.65.Any significance ? Edit: Thanks freemoney1 I think you are spot on which is good news shows confidence in Summit. | chrisatrdg | |
24/11/2016 17:22 | Black Friday Sale! Summit shares only £1:80 Previously £2.50 on 4th October and regularly over £2 since. This sale cannot last long, prices must go up in the coming months! GLA :-) | freemoney1 | |
24/11/2016 11:25 | Those 2 trades at 173.80 are both buys, I can buy on selftrade right now at 173.80. | sean cadman | |
24/11/2016 11:01 | There's a bit of a water build up behind it too | freedosh | |
24/11/2016 10:34 | Dam there's a fault in my plan | football | |
24/11/2016 10:27 | unlikely given it's Thanksgiving and the US markets closed? | waterloo01 | |
23/11/2016 17:27 | Some pre-market interest today shows there's plenty of interest still as we wait for the next RNS. I would guess the next RNS should be value changing though...Ridi/FDX comparison study OR Ridi deal. If Ridinilazole proves more effective than Fidaxomicin then it will not only be first and second line but a no brainer to use when compared to the compentition.... fingers cross for a positive study report. GLA Also, not long to wait for PhaseOut efficacy data in the scheme of things. Good to know all the stops are out now and the trials are moving ahead on both sides of the pond. Good luck to all involved. | freemoney1 | |
22/11/2016 22:10 | Late big jump on NASDAQ. Bodes well Current share price bears no relation to reality just supply and demand Longer term worth 10 - 20 times, IMO | freedosh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions